Cambrex completes $11m labs and logistics center expansion

By Vassia Barba

- Last updated on GMT

(Image: Getty/Zurijeta)
(Image: Getty/Zurijeta)

Related tags Cambrex facility Investment Laboratory Laboratory equipment

Cambrex announces the completion of a 600-square-meter facility in Karlskoga, Sweden, alongside a 3,000-square-meter warehouse.

The US-headquartered company, which recently became an integrated contract development and manufacturing organisation (CDMO) by acquiring Avista​, continued a series of investments​ at its Swedish site.

The three-story building includes process technology, QC and analytical development laboratories and is expected to house the R&D and production teams.

This investment of $5m (€4.42m), which was announced in 2018​, is expected to employ computer modeling to optimize reactor set ups and plant conditions to improve technology transfer between the teams.

According to the company, the laboratory also includes high pressure reaction vessels and crystallization equipment for drug substance manufacturing, extending the capabilities for handling in-process and raw material analysis.

The equipment is also expected to expand the temperature range at which reactions can be carried out, with vessels capable of managing conditions from cryogenic levels to nearly 200°C.

“The new technical laboratory will act as a hub for the company’s engineers, operators and chemists to ensure smooth scale up and handover of processes from development sites across our global network,”​ said Bjarne Sandberg, managing director at Cambrex.

In order to support the site’s growth, which has included the expansion of large scale manufacturing capacity, Cambrex also opened a $6m, 3,000-square-meter logistics center.

The warehouse is current good manufacturing practice (cGMP)-compliant, with integral temperature monitoring and control, and has the capacity for 4,500 pallets.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more